Clinical-stage biopharmaceutical company Vir Biotechnology Inc (Nasdaq:VIR) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer.
VIR-5500 is being co-developed by Vir Biotechnology and Astellas Pharma (TYO:4503) under a global strategic collaboration.
The therapy is being evaluated in a Phase 1 study across six dose-expansion cohorts, including monotherapy and combination regimens targeting different stages and treatment settings of prostate cancer.
Earlier Phase 1 data showed that VIR-5500 was generally well tolerated and demonstrated promising anti-tumour activity in patients with metastatic castration-resistant prostate cancer.
Fast Track designation is intended to facilitate and expedite development and review of treatments for serious conditions with unmet medical needs.
Phase 3 trials for VIR-5500 are anticipated to begin in 2027.
FDA approves second Reykjavik manufacturing suite for AVT02
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
DBV Technologies submits FDA application for VIASKIN Peanut Patch in children
Egetis Therapeutics receives FDA approval for EMCITATE in MCT8 deficiency
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC